French national diagnostic and care protocol for Kawasaki disease

Kawasaki disease (KD) is an acute vasculitis with a particular tropism for the coronary arteries. KD mainly affects male children between 6 months and 5 years of age. The diagnosis is clinical, based on the international American Heart Association criteria. It should be systematically considered in children with a fever, either of 5 days or more, or of 3 days if all other criteria are present. It is important to note that most children present with marked irritability and may have digestive signs. Although the biological inflammatory response is not specific, it is of great value for the diagnosis. Because of the difficulty of recognising incomplete or atypical forms of KD, and the need for urgent treatment, the child should be referred to a paediatric hospital as soon as the diagnosis is suspected. In the event of signs of heart failure (pallor, tachycardia, polypnea, sweating, hepatomegaly, unstable blood pressure), medical transfer to an intensive care unit (ICU) is essential. The standard treatment is an infusion of IVIG combined with aspirin (before 10 days of fever, and for a minimum of 6 weeks), which reduces the risk of coronary aneurysms. In case of coronary involvement, antiplatelet therapy can be maintained for life. In case of a giant aneurysm, anticoagulant treatment is added to the antiplatelet agent. The prognosis of KD is generally good and most children recover without sequelae. The prognosis in children with initial coronary involvement depends on the progression of the cardiac anomalies, which are monitored during careful specialised cardiological follow-up.

OP0220 CRITERIA ASSOCIATED WITH TREATMENT DECISIONS IN JUVENILE IDIOPATHIC ARTHRITIS WITH A FOCUS ON ULTRASONOGRAPHY: RESULTS FROM THE JIRECHO COHORT

Background

Treatment of children with juvenile idiopathic arthritis (JIA) is a major challenge in paediatric rheumatology. The presence of synovitis, which is difficult to detect in children, is associated with structural damage. Musculoskeletal ultrasonography (MSUS) can be used in JIA patients to reveal subclinical synovitis.

Objectives

Our aim was to determine if the use of MSUS is associated with therapeutic modifications in JIA. Secondary outcomes were to identify other factors associated with therapeutic modifications.

Methods

We conducted an observational study based on the JIRECHO multicentre cohort which was developed to provide a systematic MSUS follow-up for JIA patients. Follow-up occurred every six months and included clinical and US examinations. We included children who underwent MSUS of the elbows, wrists, second metacarpophalangeal joints, knees and ankles. Synovitis in US was defined by the presence of joint effusion and/or synovial hypertrophy in B-mode (≥ grade 1) associated or not with Doppler signals (≥ grade 1). US was performed by expert sonographers with good experience in the field of JIA who previously participated in the study of the reliability of the OMERACT paediatric US synovitis definitions and scoring system in JIA (1). Clinical and biological data, disease activity score and information on therapeutics were collected.

Results

We included 112 patients with 185 visits in total. Three groups of patients were defined according to their therapeutic status: increased(22%), decreased(14%) or stable(64%) treatment. First, we compared patients with treatment escalation with the other patients. Patients with “increased treatment” had more synovitis in B-mode US than the other patients (80% vs. 65%, p=0.06). There was no difference for the presence of synovitis in Power Doppler (PD) US (30% vs 23%, p=0.4). Patient’s and physician’s visual analogue scale (VAS) scores were significantly higher in patients with therapeutic escalation [3.3 vs 1.7, p<0.01 and 3.6 vs 1.6, p<0.0001] as well as disease activity score and inflammatory biological markers. Then, we compared patients with therapeutic de-escalation with the other patients. There was no difference in the presence of synovitis in US when compared with patients with stable treatment (62% vs. 69%, p=0.5) but there was less synovitis in B-mode ≥ grade 2 (8% vs. 24%, p=0.05).

We performed ROC curves analysis that showed that the sensitivity and specificity of the US in B-mode was similar to the physician’s VAS, disease score activity or inflammatory biological markers (Figure 1).

Figure 1.

ROC curves for clinical and biological items and US in B-mode in patients with « therapeutic escalation »

Conclusion

In our study, MSUS of ten joints was not statistically associated with treatment escalation or de-escalation in B-mode and PD in patients with JIA.

References

[1]Rossi-Semerano, L. et al. Application of the OMERACT synovitis ultrasound scoring system in juvenile idiopathic arthritis: a multicenter reliability exercise. Rheumatol. Oxf. Engl. (2020) doi:10.1093/rheumatology/keaa804.

Disclosure of Interests

None declared

POS1326 PIMS THROUGH THE WAVES OF COVID 19: DATA FROM THE JIR COHORT

Background

Paediatric inflammatory multisystem Syndrome (PIMS) is a new systemic inflammatory disease linked to SARS-CoV2 that affects children. It was first reported in may 2020 [1-2].

Objectives

The objectives of this study were to describe patients with PIMS through the international JIR cohort registry and to compare the different profiles and treatments of these patients over the different waves.

Methods

Study patients with international PIMS criteria were included from March 2020 to June 2021. Patients were identified in the JIR cohort, an international registry collecting demographic, clinical and paraclinical data on patients with pediatric inflammatory diseases. Two groups were distinguished: from March 2020 to July 2020 for patients in the first wave, from July 2020 to June 2021 for patients in the 2nd and 3rd waves. These two groups were compared using a Fischer test for categorical data and a Mann-Whitney test for quantitative data

Results

136 patients meeting the PIMS criteria were included (64 patients in the 1st wave, 72 patients after). Patients had less frequent myocarditis (51 patients in wave 1 vs. 36 patients after, p=0,0003) and respiratory distress (34 patients vs 10 patients, p<0,0001). Corticosteroids were used more frequently in the second wave (32 patients in wave 1 vs. 67 patients after July 2020, p<0,0001). Intravenous immunoglobulins were used as much over the waves (58 patients in wave 1 vs 68 patients after, p=0.5). Antibiotics were less used since the second wave (53 patients received antibiotics before July 2020 vs 11 after, p<0,0001). The duration of hospitalization decreased significantly (p<0,0001) with a median duration of 9 days during the first wave (interquartile range, 7-12) and 7 days (interquartile range, 5-10) after the first wave.

Conclusion

There was a decrease in the number of complications of PIMS, particularly cardiac and respiratory complications, and a decrease in the length of hospitalization over time. The treatment of PIMS has also evolved, with a clear increase in the use of corticosteroids and a decrease in the use of antibiotics.

References

[1]Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P (2020) Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395:1607–1608.

[2]Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D’Antiga L (2020) An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 395:1771–1778

Acknowledgements

Acknowldgements to the French Covid-19 Paediatric Inflammation Consortium.

Disclosure of Interests

None declared

POS1325 CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS (CRMO): NEW INSIGHTS INTO EXTRA-OSSEOUS MANIFESTATIONS

Background

Chronic recurrent multifocal osteomyelitis (CRMO) is a rare inflammatory disease of the skeleton characterized by chronic and recurrent episodes of osteo-articular inflammation. The median age of onset is 10 years old. Clinical manifestations include musculoskeletal symptoms that are well described (pain, tenderness, swelling). Sometimes, skin lesions or digestive manifestations occur. Whole body magnetic resonance imaging (MRI) is the gold standard for assessing the multifocal pattern of the CRMO. Treatment is still empirical and mainly relies on non-steroidal anti-inflammatory drugs (NSAIDs). Bisphosphonates and biologics are used as second-line treatments. To date, the focus has been set on bone involvement and very few data are available on extra-osseous manifestations in CRMO.

Objectives

This study aims to further describe these extra-osseous clinical manifestations in CRMO.

Methods

A historical cohort was designed using 61 CRMO patients at the Pediatric Rheumatology Department in a tertiary university hospital in Paris (Hôpital Bicêtre, France). All patients underwent a MRI that confirmed the diagnosis according to the criteria of Jansson. Skeletal involvement was characterized with 1/axial, 2/ peripheral, 3/ axial and peripheral lesions. Extra-osseous manifestations were divided into 1/ skin lesions, 2/ gastro-intestinal manifestations, 3/ enthesitis and 4/ others. Pain was evaluated thanks to the Visual Analog Scale (VAS, from 0 to 10). Treatments used were recorded. The study complied with ethical requirements.

Results

Forty one patients were included in the study, with 31 females (75.6%). The mean ± SD age at onset was 79.1 ± 59.8 months, with a delay at diagnosis beyond six months (6.71 ± 6.96). Twenty-one patients had a familial history of inflammatory diseases (51.2%), with a majority of psoriasis or ankylosing spondylitis (n=13/21, 61.9%). At diagnosis, the level of pain was 5.71 ± 3.24. Eleven patients (42.3%) had blood inflammation. Bone lesions were reviewed thanks to whole body MRI: four patients had isolated axial involvement (10.0%), nine had peripheral involvement (22.5%) and 27 patients harbored both types of lesions (67.5%). The mean number of lesions was 6.65 ± 4.23. After 12 months of follow-up, all parameters regarding disease’s activity decreased (pain, blood inflammation, number of lesions). Regarding extra-osseous symptoms, fever occurred in seven patients (17.1%). Twenty-four patients had skin manifestations (58.5%) with palmoplantar lesions (n=3, 12.5%), acne (n=6, 25.0%), psoriasis (n=5, 20.8%) and aphthous (n=10, 41.7%). Four patients (9.76%) had gastro-intestinal symptoms and seven (17.1%) had enthesitis. One patient had uveitis. Almost all patients received NSAIDs (n=39/41, 95.1%) and half of the cohort were treated with bisphosphonates (n=21/41, 51.2%). Nine patients (22.0%) received biologics with a majority of TNF inhibitors. All patients that received TNF inhibitors had either a cutaneous involvement or digestive symptoms or enthesitis (Figure 1).

Conclusion

Extra-osseous manifestations have to be carefully searched in CRMO, especially in the presence of familial history of inflammatory diseases. While the severity of bone involvement can lead to use bisphosphonates, the introduction of biologics seems to rely on extra-osseous symptoms. These conclusions are drawn on a retrospective study and need to be confirmed in larger cohort.

References

[1]Wipff J, et al. A large national cohort of French patients with chronic recurrent multifocal osteitis. Arthritis Rheumatol 67, 1128-1137 (2015).

[2]Jansson A, et al. Classification of Non-Bacterial Osteitis: Retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology 46, 154-160 (2006).

Disclosure of Interests

None declared

Caractéristiques cliniques de la Covid-19 chez les enfants et adolescents atteints de maladies rhumatismales et inflammatoires : données de la cohorte française RMD COVID-19 de 95 patients

Introduction

Patients et méthodes

Résultats

Conclusion

[Osteomyelitis in cat scratch disease: a case report and literature review]

Cat scratch disease is the most common zoonosis in humans and its typical expression is a persistent benign regional adenopathy. In some rare cases, mono- or multifocal osteomyelitis is described. In this paper, we report the case of bone lesions in a 13-year-old girl infected with cat scratch disease. We have also undertaken a literature review and analyzed 60 other such cases. The manifestation of a bone lesion associated with cat scratch disease was characterized by a mono- or multifocal infectious osteomyelitis, fever, and a general alteration of the patient's health. The most frequent location of osteomyelitis was in the spine. Magnetic resonance imaging appeared the most sensitive test to highlight the bone lesions. Serological findings help reinforce the diagnosis of cat scratch disease caused by Bartonella henselae infection. Osteomyelitis in cat scratch disease is rare but not exceptional. Therefore, it is essential to think about this hypothesis in case of osteomyelitis associated with a general alteration of the patient's health, especially if the lesions are multifocal and if there is a known history of cat contact.